Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
883.20
-7.48 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
35
36
Next >
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
November 15, 2021
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,...
Via
Benzinga
5 Stocks To Watch For November 15, 2021
November 15, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Warner Music Group Corp. (NYSE: WMG) to report quarterly earnings at $0.15 per share on revenue...
Via
Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
November 12, 2021
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products.
Via
Talk Markets
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
November 12, 2021
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and...
Via
Benzinga
Exposures
COVID-19
Ligand Pharmaceuticals Sees RS Rating Rise To 92
November 11, 2021
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance.
Via
Investor's Business Daily
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
November 11, 2021
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc...
Via
Benzinga
Exposures
COVID-19
When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla
November 08, 2021
Teslas getting charged in a Wawa parking lot last month. Photo via author. When Winning Streaks Stop In a post in August (Tesla And The Quest For Alpha), we wrote about how a...
Via
Benzinga
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
November 08, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg...
Via
Benzinga
Exposures
COVID-19
When Winning Streaks Stop
November 07, 2021
Trying to beat the market by buying stocks like Tesla. It's probably impossible to time these things perfectly, but as we continue to collect data, we may be able to spend more time in winning...
Via
Talk Markets
Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
November 05, 2021
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition...
Via
Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
November 05, 2021
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
November 05, 2021
Upgrades For IGM Biosciences Inc (NASDAQ:
Via
Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
November 05, 2021
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
3 Reasons Why Investors Should Love Regeneron's Q3 Update
November 05, 2021
The big biotech delivered an exceptionally strong performance in Q3.
Via
The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 Earnings Call Transcript
November 04, 2021
REGN earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
7 European Stocks to Buy to Diversify Your Portfolio
November 04, 2021
While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks.
Via
InvestorPlace
Regeneron Pharmaceuticals Earnings Perspective: Return On Invested Capital
November 04, 2021
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q3 earnings of $1.85 billion, an increase from Q2 of 44.81%. Sales dropped to $3.45 billion, a 32.81...
Via
Benzinga
Why Regeneron Shares Are Rising Today
November 04, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced better-than-expected third-quarter financial results. Regeneron reported...
Via
Benzinga
How Regeneron's Covid Drug Lent Itself To A Big Third-Quarter Beat
November 04, 2021
Regeneron reported $804 million in sales of its Covid antibody cocktail, REGEN-COV.
Via
Investor's Business Daily
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
Healthcare Stocks Subject to Government Policy
November 02, 2021
The market this morning isn’t moving much, but today’s tepid start is coming on the heels of yesterday’s record closes on the Dow, the S&P 500, and the...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
October 29, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...
Via
Benzinga
Will Regeneron Be Worth More Than Amazon by 2030?
October 28, 2021
Regeneron's market value has climbed more than 1,000% in a decade.
Via
The Motley Fool
Exposures
COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
October 26, 2021
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Exposures
Product Safety
Moderna Slapped With Sell Rating Despite CDC Authorization For Covid Boosters
October 22, 2021
The CDC authorized boosters from J&J, Moderna and a mix-and-match approach.
Via
Investor's Business Daily
The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
October 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Athira Names Chief Operating Officer Mark Litton As Next CEO as Leen Kawas...
Via
Benzinga
The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO
October 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CDC Committee Recommends Approval Of Merck, Pfizer's Pneumococcal Vaccine...
Via
Benzinga
Exposures
Product Safety
Esperion Chops 40% Workforce As Launch Of Cholesterol Medication Falters
October 18, 2021
Esperion Therapeutics Inc's (NASDAQ: ESPR) cholesterol drug marketing strategy has soured badly, as it has been struggling to sell its heart disease pill for more than a...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
33
...
35
36
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.